EirGenix Inc. (TPE:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
63.10
-0.30 (-0.47%)
At close: Jan 9, 2026
-15.75%
Market Cap19.28B
Revenue (ttm)936.18M
Net Income (ttm)-705.76M
Shares Out302.60M
EPS (ttm)-2.33
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume302,663
Average Volume809,815
Open63.40
Previous Close63.40
Day's Range62.40 - 63.80
52-Week Range52.70 - 84.30
Beta0.59
RSI39.28
Earnings DateMar 18, 2026

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 207
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.

Financial Statements

News

There is no news available yet.